Shareholder Alert: The Ademi Firm investigates whether LAVA Therapeutics N.V. is obtaining a Fair Price for its Public Shareholders in the Amendment to the Purchase Agreement

Under the Amendment, LAVA shareholders will receive (i) an initial cash amount per share of $1.04 as compared to the range between $1.16 and $1.24 that was originally agreed, plus (ii) a non-transferable contingent value right per share representing the right to receive certain cash payments under certain conditions.  In addition, LAVA and XOMA Royalty have agreed to amend LAVA's minimum net-cash closing condition to be $24.5 million, compared to the previous minimum net-cash closing condition of $31.5 million.

Lava insiders will continue to receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for Lava by imposing a significant penalty if Lava accepts a competing bid. We are investigating the conduct of the Lava board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Ademi & Fruchter LLP                                 
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholder-alert-the-ademi-firm-investigates-whether-lava-therapeutics-nv-is-obtaining-a-fair-price-for-its-public-shareholders-in-the-amendment-to-the-purchase-agreement-302588246.html

SOURCE Ademi LLP